Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This study found that the dissolution profiles of different finasteride polymorphs may affect the quality of finasteride capsules, highlighting the need for polymorphic quality control.

This study found that a phytosomal delivery system improved the bioavailability of Cuscuta reflexa extract compared to the plain extract, suggesting enhanced potential for this formulation.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

This study investigated the effects of cedrol on colorectal cancer and found that it inhibited cell proliferation and induced cell cycle arrest and apoptosis in cell models, while in vivo, it suppressed cancer progression and improved survival at a well-tolerated dose.

This study found that AHCC significantly reduced alopecia caused by Ara-C in neonatal rats and improved liver function affected by 6-MP and MTX in mice.

In this study, the researchers reported that a newly developed PYGL inhibitor, HTPI, enhanced hair growth in an ex-vivo culture by reducing oxidative damage in hDPCs and inhibiting glycogen degradation in hORSCs, showing potential as a treatment for hair loss comparable to minoxidil.

This paper describes a new scalable synthesis method for Dutasteride, highlighting its potential for large-scale commercial production.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.

This study developed three spectrophotometric methods to effectively measure finasteride in bulk and tablet forms, providing accurate results that align closely with labeled claims.

This study concluded that clomiphene citrate is generally preferred over metformin for inducing ovulation in obese women with PCOS, despite low-quality evidence indicating metformin may be superior to placebo for live births.

Agomelatine might help reduce hair loss caused by valproate.

This study found that several compounds from Yangxue Shengfa capsule may promote hair growth by enhancing cell proliferation in vitro, suggesting potential use in treating androgenetic alopecia.

This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that compliance rates for oral contraceptives are low and similar to those for other medical treatments, indicating a need for alternatives that require less daily adherence.

This study observed that a tacrolimus solution (0.1%) applied to the scalp was effective and well-tolerated for treating inflammatory scalp conditions, with 72.7% of patients showing an excellent response after 2 months of treatment, which persisted after 6 months.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

In this study, Ocoxin used alongside chemotherapy may improve patients' tolerance to treatment and their quality of life without significant safety concerns, although further research is needed.

This study examined treatments for emesis in young Alexander disease patients, finding that 95% responded positively to valproic acid, which was more effective than anti-reflux medications or cyproheptadine, though some adverse effects require monitoring.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study found that once-daily oxiconazole cream effectively treats tinea infections, achieving at least 80% cure rates, and shows comparable efficacy to other antifungal creams with similar tolerability.

The FDA approved using Cialis with Proscar for better treatment options.

This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.

This study found that a PRP-like cosmetic product called TR-M-PRP plus significantly improved hair growth in individuals with alopecia areata over three months, as measured by the SALT score, suggesting it could be a safer alternative to traditional PRP treatments.